Latest Breaking News On - John shen - Page 4 : comparemela.com

ARX517 Demonstrates Early Efficacy With Favorable Safety in Heavily Pretreated mCRPC

ARX517 displayed preliminary efficacy and a strong safety profile in patients with metastatic castration-resistant prostate cancer, according to findings from the phase 1/2 APEX-01 study.

United statesJohn shenLos angelesOncology department at jonsson comprehensive cancer centerMedical oncology departmentJonsson comprehensive cancer centerMetastatic castration resistant prostate cancerProstate cancerAntibody drug conjugatePsma targeted adcApex 01 studyEsmo congress

Ambrx (AMAM) Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO Congress

Ambrx (AMAM) Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO Congress
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDanielj oconnorShawn zhangDavid millsScottt tagawaJohn shenAmbrx biopharma incEuropean society of medical oncologyAmbrx biopharmaMedical oncologyKey opinion leaderFirst in human phaseChief executive officerProstate cancer posterBasic science poster

Ambrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO Congress

Newly published abstract regarding dose escalation patients provides key updates including: ≥50% PSA reduction observed across putative therapeutic dose levels ≥2.0 mg/kg – 3 of 3 in Cohort 6.

United statesJohn shenDavid millsDanielj oconnorKarissa crossMike moyerShawn zhangScripps research instituteGlobenewswire incEuropean society of medical oncologyLifesci communicationsAmbrx biopharma incMedical oncologyKey opinion leaderFirst in human phaseChief executive officer

Ambrx Provides Safety and Efficacy Data from Ongoing Phase

Newly published abstract regarding dose escalation patients provides key updates including: ≥50% PSA reduction observed across putative therapeutic dose.

United statesDanielj oconnorShawn zhangKarissa crossScottt tagawaJohn shenDavid millsMike moyerEuropean society of medical oncologyAmbrx biopharma incScripps research instituteLifesci communicationsMedical oncologyKey opinion leaderFirst in human phaseChief executive officer

Irvine City Council approves Letter Of Intent with Sunstone Management for early-stage business accelerator

Irvine City Council approves Letter Of Intent with Sunstone Management for early-stage business accelerator
publicceo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publicceo.com Daily Mail and Mail on Sunday newspapers.

City of irvineUnited statesLong beachFarrah khanEric romeroJohn shenTammy kimJohn keislerCity councilBeall centerUniversity of californiaSunstone management incIrvine innovation councilIrvine city councilAmerica fastest growing companiesPaul merage school of business